Abstract

Background: Eosinophils develop from CD34 + progenitors under the influence of IL-5. Atopic asthmatic individuals have increased numbers of mature eosinophils and eosinophil pro-genitors within their bone marrow and bronchial mucosa. We have previously reported that anti–IL-5 monoclonal antibody treatment decreases total bone marrow and bronchial mucosal eosinophil numbers in asthma. Objective: Using an anti–IL-5 monoclonal antibody, we examined the role of IL-5 in eosinophil development within the bone marrow and bronchial mucosa in asthma. Methods: Blood, bone marrow, and airway mucosal biopsy specimens were examined before and after anti–IL-5 (mepolizumab) treatment of asthmatic individuals in a double-blind, placebo-controlled trial. Numbers of mature and immature eosinophils were measured by histologic stain (bone marrow myelocytes, metamyelocytes, and mature eosinophils), flow cytometry (bone marrow and blood CD34 +/IL-5Rα + cells), enumeration of bone marrow–derived eosinophil/basophil colony-forming units in methylcellulose culture, and sequential immunohistochemistry and in situ hybridization (bronchial mucosal CD34 +/IL-5Rα mRNA + cells). Results: Mepolizumab decreased mature eosinophil numbers in the bone marrow by 70% ( P = .017) in comparison with placebo and decreased numbers of eosinophil myelocytes and metamyelocytes by 37% ( P = .006) and 44% ( P = .003), respectively. However, mepolizumab had no effect on numbers of blood or bone marrow CD34 +, CD34 +/IL-5Rα + cells, or eosinophil/basophil colony-forming units. There was a significant decrease in bronchial mucosal CD34 +/IL-5Rα mRNA + cell numbers in the anti–IL-5 treated group ( P = .04). Conclusion: These data suggest that anti–IL-5 therapy might induce partial maturational arrest of the eosinophil lineage in the bone marrow. The reduction in airway CD34 +/IL-5 mRNA + cell numbers suggests that IL-5 might also be required for local tissue eosinophilopoiesis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call